Louis Stancato received a B.S. in Cellular and Molecular Biology and a Ph.D. in Pharmacology from the University of Michigan. A 22 year veteran of Lilly, Lou most recently was a group leader in Oncology Translational Research, where he was a champion of pediatric cancer. His team was responsible for preclinical data packages to directly support development of the Oncology clinical portfolio, including Verzenio, Cyramza, Lartruvo, prexasertib and LY3295668.
Lou is currently the co-leader of an Innovative Medicines Initiative 2 project entitled “A Comprehensive ‘Paediatric Preclinical Proof-of-Concept Platform’ to Enable Clinical Molecule Development for Children with Cancer (ITCC-P4).” This 23-member multinational public-private partnership brings together many of the EU’s top pediatric research centers with scientists from Bayer, J&J, Pfizer, PharmaMar, Roche and Lilly, and has created a world-class preclinical pediatric research platform. The platform’s goal is to deliver innovative, life-saving medicines to children with cancer and will support research needs anticipated to arise in the changing regulatory landscape. Currently in its fourth year, ITCC-P4 is fully operational with drug efficacy testing underway in the EU. Recently, Lou joined the Pediatrics Capability Group in the Lilly Medical organization, where he will continue to passionately support pediatric cancer development while expanding into other areas of childhood affliction.